Vantage Markets celebrates Copy Trading success with viral video campaign, featuring duets by top influencers from India and Vietnam

Vantage Markets celebrates Copy Trading success with viral video campaign, featuring duets by top influencers from India and Vietnam

PORT VILA, Vanuatu, Dec. 5, 2024 /PRNewswire/ -- In celebration of 15 years of empowering traders, Vantage Markets ("Vantage") is thrilled to announce the resounding success of its latest copy trading video campaign, Join the Move, Mirror the Trade....

THE COUNTDOWN BEGINS TO THE TRAILBLAZING GAMES OF THE FUTURE 2025

THE COUNTDOWN BEGINS TO THE TRAILBLAZING GAMES OF THE FUTURE 2025

DUBAI, UAE, Dec. 5, 2024 /PRNewswire/ -- Phygital International today announces that the Games of the Future 2025, hosted in the UAE will kick off on 21st November. The action-packed, multi-day tournament promises to be the undisputed highlight of...

Gr4vy welcomes JustGiving as a new client and introduces Gr4vy Pulse

Gr4vy welcomes JustGiving as a new client and introduces Gr4vy Pulse

SAN MATEO, Calif., Dec. 4, 2024 /PRNewswire/ -- Gr4vy , the cloud-native payment orchestration layer, announces JustGiving, the UK's leading online fundraising platform. Through Gr4vy's innovative payment orchestration platform, JustGiving supports...

Rhein Laser Announces FDA 510(k) Clearance of UroFiber 60Q

Rhein Laser Announces FDA 510(k) Clearance of UroFiber 60Q

The Most Powerful Thulium SuperPulsed Fiber Laser for Urology is Here WUHAN, China, Dec. 4, 2024 /PRNewswire/ -- Rhein Laser Technologies Co., Ltd. is proud to announce that its UroFiber® 60Q SuperPulsed Thulium Fiber Laser System received FDA...

Secureworks Announces Third Quarter Fiscal 2025 Results

Secureworks Announces Third Quarter Fiscal 2025 Results

ATLANTA, Dec. 4, 2024 /PRNewswire/ -- Secureworks® (NASDAQ: SCWX), a global leader in cybersecurity, today announced financial results for its third quarter fiscal 2025, which ended on November 1, 2024. Key Highlights Taegis™ third quarter revenue...

Instacoins Announces New Partnerships with Luxury Goods Companies for Digital Payment Acceptance

Instacoins Announces New Partnerships with Luxury Goods Companies for Digital Payment Acceptance

SOFIA, Bulgaria, Dec. 4, 2024 /PRNewswire/ -- Instacoins is very pleased to announce new partnerships with leading private jet service "ELBJETS", luxury yacht charter company "Luxury Catamarans", and premium timepiece specialist "Watchrr". High-end...

Gaotu Techedu Announces Third Quarter 2024 Unaudited Financial Results

Gaotu Techedu Announces Third Quarter 2024 Unaudited Financial Results

BEIJING, Dec. 4, 2024 /PRNewswire/ -- Gaotu Techedu Inc. (NYSE: GOTU) ("Gaotu" or the "Company"), a technology-driven education company and online large-class tutoring service provider in China, today announced its unaudited financial results for...

YES announces release of VertaCure XP G3 Systems for Advanced Packaging Applications

YES announces release of VertaCure XP G3 Systems for Advanced Packaging Applications

YES announced today that it is releasing the 3rd generation VertaCure curing systems for use in manufacturing advanced packaging solutions. FREMONT, Calif., Dec. 4, 2024 /PRNewswire/ -- Yield Engineering Systems (YES) is a leading manufacturer of...

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission. In the high dose cohort, 6 out of 7 (85.7%) patients...

VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery

VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery

VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery Statistically and clinically...

  • 1
  • ...
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • ...
  • 20
  • menu
    menu